Engineered Platelet Drug Delivery for Protein Therapeutic Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing platelets are limited by donor shortages, functional variability, and inefficiencies in delivering therapeutic drugs, particularly protein-based therapeutics, which are needed for effective drug delivery and on-demand platelet production.
Innovation Solution
The development of induced pluripotent stem cell (iPSC)-derived megakaryocytic progenitors, megakaryocytes, proplatelets, and platelets, which can be loaded with therapeutic agents through receptor-mediated loading, passive loading, or covalent conjugation, and genetically engineered to express drugs, enabling scalable production and targeted drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nanoparticle-based approaches are used for drug delivery, then delivery to target sites is improved, but accumulation efficiency remains low (less than 1%) and adverse immune responses occur
Solution Approach 1:
The patent uses platelets as intermediary carriers to deliver therapeutic agents to target sites. Platelets naturally circulate in the bloodstream and can be engineered to carry drugs, proteins, or other therapeutics, serving as a biological mediator between the therapeutic agent and the target tissue, thereby avoiding direct injection of nanoparticles that trigger immune responses.
Solution Approach 2:
The patent leverages the natural physiological functions of platelets for drug delivery. Platelets naturally accumulate at sites of injury or disease through their inherent homing capabilities, and the patent exploits this self-targeting behavior to deliver therapeutics without requiring external guidance systems or suffering from the low accumulation efficiency of conventional nanoparticles.
2Quantity of substance
If conventional nanoparticle formulations are used, then small molecule delivery is enhanced, but protein-based therapeutics cannot be effectively packaged due to size constraints
Solution Approach 1:
The patent changes the size parameter of the delivery vehicle from nanoscale particles to microscale platelets (2-10 micrometers in diameter). This parameter change allows the carrier to accommodate large protein-based therapeutics, antibodies, and other macromolecules that cannot be packaged in conventional nanoparticles, while still maintaining circulation and target delivery capabilities.
3Reliability
If donor-derived platelets are used, then immediate therapeutic effect is achieved, but donor shortages and functional variability limit availability and effectiveness
Solution Approach 1:
The patent creates artificial platelet copies through genetic engineering of cell lines (such as HEK293 or CHO cells) to produce platelet-like particles or engineered platelets that replicate the functional properties of donor platelets. This copying approach eliminates dependence on human donors while maintaining the desired therapeutic functions, including drug delivery capabilities and physiological responses.
Data Source
AI summary
Methods for producing megakaryoctyres and platelets derived from inducible pluripotent stem cells and comprising a therapeutic agent are provided. The present disclosure further provides methods and compositions for loading a platelet or a megakaryocyte with a therapeutic agent and for genetically modifying a platelet or a megakaryocyte to express an agent.